Welcome to our dedicated page for Biovaxys Technol news (Ticker: BVAXF), a resource for investors and traders seeking the latest updates and insights on Biovaxys Technol stock.
BioVaxys Technology Corp. (OTCQB: BVAXF) is a clinical-stage biopharmaceutical company whose news flow centers on its DPX™ immune-educating platform, oncology vaccine programs, and licensing activities. Company releases describe DPX as a non-systemic antigen delivery technology used to generate targeted and persistent immune responses, with applications in cancer, infectious disease, and antigen desensitization.
Investors following BVAXF news can expect updates on clinical studies of maveropepimut-S (MVP-S) in advanced relapsed-refractory diffuse large B cell lymphoma and platinum-resistant ovarian cancer, as well as early-stage work in non-muscle invasive bladder cancer and HR+/HER2- breast cancer. News items also highlight DPX+SurMAGE, a dual-targeted immunotherapy for bladder cancer, and DPX-based vaccines such as DPX-RSV and DPX+rPA for anthrax.
BioVaxys regularly reports on collaborations and licensing agreements that leverage its lipid-based technologies. Examples include licensing to SpayVac-for-Wildlife, Inc. for single-dose immunocontraceptive vaccines in wildlife and aquaculture, and to Zoetis Inc. for animal health applications. The company also issues updates on research collaborations, such as combining DPX with Sona Nanotech’s Targeted Hyperthermia Therapy™ and exploring DPX as a carrier for mRNA vaccines.
In addition to scientific and clinical developments, BVAXF news covers corporate actions such as amendments to its asset purchase agreement for the DPX portfolio, share consolidation on the Canadian Securities Exchange, and financing-related milestones. For readers tracking BVAXF, this news page aggregates these disclosures so they can monitor progress of the DPX platform, pipeline evolution, and key partnership developments over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
BioVaxys Technology Corp. (OTCQB: BVAXF) announced on April 17, 2023, that it has engaged Maxim Group LLC as a financial advisor and investment banker. The firm will assist with financial advisory and investment banking services, focusing on strategic planning, alliances, and US national stock exchange listing processes. BioVaxys has agreed to issue 2,902,236 common shares to Maxim, pending approval from the Canadian Securities Exchange. CEO James Passin expressed enthusiasm about working with Maxim to enhance shareholder value and explore transformative capital market opportunities. BioVaxys specializes in developing vaccines for various viruses and cancers, including a potential vaccine for Stage III/IV ovarian cancer.
BioVaxys Technology Corp. (OTCQB: BVAXF) announced the acquisition of TAETSoftware Corp, a Vancouver-based clinical studies management company. The deal involved issuing 24.5 million common shares, with an additional 2.5 million shares contingent on successful beta testing of the Trial Adverse Events Tracker (TAET) platform. This innovative application allows real-time reporting of adverse drug events in clinical trials, improving data accuracy and responsiveness. Additionally, BioVaxys completed a private placement, raising $670,000 through the issuance of 5.36 million shares. The company aims to utilize these funds for working capital and will leverage TAET to enhance revenue opportunities in the clinical study sector.
BioVaxys Technology Corp. has finalized a US Distribution Agreement with Procare Health Iberia for Papilocare® and Oral Immunocaps©. Papilocare® is a patented vaginal gel for preventing and treating HPV-related cervical lesions, with proven efficacy in clinical trials. BioVaxys will pursue FDA approval for Papilocare®, while Immunocaps© can be marketed without regulatory hurdles. The agreement also includes future discussions on other Procare products for women's health. This collaboration aims to expand access to innovative treatments for cervical health in the US market.
BioVaxys Technology Corp. (OTCQB: BVAXF) announces that Co-Founder, President & COO Kenneth Kovan will present at the MedInvest Oncology Investor Conference in New York City on December 14-15, 2022. This event, in partnership with the National Foundation for Cancer Research, gathers oncology-focused investors and companies. Kovan, with over 30 years of biopharma experience, will discuss BioVaxys' haptenized protein platform for cancer immunotherapies, including developments for ovarian cancer. The conference features industry leaders and is supported by the National Cancer Institute.
BioVaxys Technology Corp. has successfully completed a sterile test-run production of its BVX-0918 ovarian cancer vaccine, validating the production protocols developed over recent months. This involved extracting tumor cells from a cancer patient and significantly reducing production time by 50%. The company now aims to optimize the vaccine production process and prepare for regulatory submission in the EU. BioVaxys is advancing its clinical studies with Procare Health Iberia for a Phase I trial, marking a significant milestone in their cancer vaccine development.
BioVaxys Technology Corp. has signed a binding agreement with Procare Health for the exclusive marketing and distribution of their HPV treatment product, Papilocare, and the immune-support supplement Immunocaps in the US. This agreement grants BioVaxys a right of first refusal for Procare's other products, Ovosicare and Libicare. BioVaxys anticipates rapid revenue generation from Immunocaps, which does not require FDA approval. The partnership also involves milestone payments and royalties. Regulatory approval for Papilocare as a Class II medical device is expected.